Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors.

Naoko Takebe Abdul Rafeh Naqash Geraldine O'Sullivan CoyneShivaani KummarKhanh DoAshley BrunsLamin JuwaraJennifer ZlottLawrence V Rubinstein Richard L Piekarz Elad SharonHoward StreicherArjun MittraSarah B MillerJiuping JiDeborah WilskerRobert J KindersRalph E ParchmentLi ChenTing-Chia ChangBiswasjit DasGanesh MugunduJames H Doroshow Helen X Chen

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

We determined the once-daily adavosertib RPh2D and observed activity in patients with ovarian or endometrial carcinoma, including two with baseline CCNE1 mRNA overexpression. Future studies will determine whether CCNE1 overexpression is a predictive biomarker for adavosertib.

Keyphrases

cell proliferation
physical activity
transcription factor
clinical trial
study protocol
phase iii
current status
phase ii
endometrial cancer
binding protein
case control